Novosanis, an innovative developer and producer of medical devices, announced their collaboration with Saltro, an innovative diagnostic centre with headquarters in Utrecht, The Netherlands.
‘Directlab’ is Saltro’s initiative to provide a better and easy accessible programme to test for STIs (Sexual Transmitted Infections). Saltro chose Novosanis’ Colli-Pee to ensure standardized first-void urine (first 20ml of urine) self-sampling.
The first test Saltro’s Directlab offers is a Chlamydia test. Although a Chlamydia infection does not cause significant problems in the beginning it can cause complications and is highly transmittable. Therefore easy access to detect the bacteria and drive the patient to a GP for treatment is key in the prevention of spreading.
Unique to this initiative is the possibility for home-based self-sampling in an easy and first-time right manner. Novosanis Colli-Pee offers the solution to collect first-void urine that can be send to the lab for analysis. This way the quality of the test is guaranteed while providing the patient the needed discretion in order to motivate him or her to take the test.
Vanessa Vankerckhoven, CEO Novosanis stated: “We are pleased that Colli-Pee is part of a disruptive new solution offering home-based self-sampling for detection of STIs. We are convinced that public health will benefit from Saltro’s Directlab initiative.”
“The advantage of inclusion Colli-Pee is that it provides a standardized first-void sample which will be beneficial for the analysis of STIs. Moreover the device can easily be shipped by postal mail to the patients’ home.” says Dr Sanne van Delft, programme manager at Saltro.
Novosanis is an innovative developer and producer of medical devices adding value to the accuracy of diagnostics tests, vaccination based actions and the overall patient’s comfort.
Saltro is an innovative diagnostic centre offering support through laboratory testing, function testing and counselling to healthcare professionals aiming to provide the best care to patients.